The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras by Brian Kelley

“…mAbs…”
Get full text

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma by Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R. Piccotti, Katie Stamp, Ho Cho, Kandasamy Hariharan

“…mAbs…”
Get full text

A tailored lectin microarray for rapid glycan profiling of therapeutic monoclonal antibodies by Shen Luo, Baolin Zhang

“…mAbs…”
Get full text

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity by Alyssa Synan, Nila C. Wu, Roberto Velazquez, Thomas Gesner, Claude Logel, Kathrin Mueller, Andrew Green, Patrizia Barzaghi-Rinaudo, Quincey Simmons, Samuele Mercan, Xingyi Shi, Xun Li, Vivek Sagar, Joshua Korn, Margaret McLaughlin, William R. Tschantz, Dominik Hainzl, Anthony Malamas, Thomas Huber, Regis Cebe, Kathleen T. Xie, Joseph A. D’Alessio

“…mAbs…”
Get full text

Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring by Adam R. Evans, Joseph Mulholland, Michael J. Lewis, Ping Hu

“…mAbs…”
Get full text

Correction

“…mAbs…”
Get full text

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy by Amelia C. McCue, Stephen J. Demarest, Karen J. Froning, Michael J. Hickey, Stephen Antonysamy, Brian Kuhlman

“…mAbs…”
Get full text

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties by Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny, Laura von Schantz

“…mAbs…”
Get full text

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics by Ruoxuan Sun, Mark G. Qian, Xiaobin Zhang

“…mAbs…”
Get full text

Reduction of monoclonal antibody viscosity using interpretable machine learning by Emily K. Makowski, Hsin-Ting Chen, Tiexin Wang, Lina Wu, Jie Huang, Marissa Mock, Patrick Underhill, Emma Pelegri-O’Day, Erick Maglalang, Dwight Winters, Peter M. Tessier

“…mAbs…”
Get full text

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

“…mAbs…”
Get full text

Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge by M. Biddle, P. Stylianou, M. Rekas, A. Wright, J. Sousa, D. Ruddy, M. I. Stefana, K. Kmiecik, A. Bandrowski, R.A. Kahn, C. Laflamme, E. M. Krockow, H.S. Virk

“…mAbs…”
Get full text

Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows by Tushar Jain, Bianka Prinz, Alexander Marker, Alexander Michel, Katrin Reichel, Valerie Czepczor, Sylvie Klieber, Wei Sun, Sagar Kathuria, Sevim Oezguer Bruederle, Christian Lange, Lena Wahl, Charles Starr, Alessandro Masiero, Lindsay Avery

“…mAbs…”
Get full text

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals by Sophie Tourdot, Daniel Baltrunkonis, Sofie Denies, Viswanath Devanarayan, Joanna Grudzinska-Goebel, Arno Kromminga, Gregor P. Lotz, Laurent Malherbe, Lydia Michaut, Karin N. Weldingh, Joao A. Pedras-Vasconcelos, Laura. I. Salazar-Fontana, Sebastian Spindeldreher, Zuben Sauna, Veerle Snoeck, Daniela Verthelyi, Daniel Kramer

“…mAbs…”
Get full text

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches by David Hoffmann, Joschka Bauer, Markus Kossner, Andrew Henry, Anne R. Karow-Zwick, Giuseppe Licari

“…mAbs…”
Get full text

Establishing endotoxin limits to enhance the reliability of in vitro immunogenicity risk assessments by Yun Hee Jeong, Gillian Lennon, Geertruida Veldman, Daniel M. Serna, Alexander Ibrahimov

“…mAbs…”
Get full text

Cost and supply considerations for antibody therapeutics by Chun Chen, Zoe Garcia, David Chen, Hong Liu, Piper Trelstad

“…mAbs…”
Get full text

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function by Jennifer L. Schwedler, Maxwell A. Stefan, Christine E. Thatcher, Peter R. McIlroy, Anupama Sinha, Ashlee M. Phillips, Christopher A. Sumner, Colleen M. Courtney, Christina Y. Kim, Dina R. Weilhammer, Brooke Harmon

“…mAbs…”
Get full text

Discovery of potent allosteric antibodies inhibiting EGFR by Léxane Fournier, Lukas Pekar, Birgitta Leuthner, Harald Kolmar, Lars Toleikis, Stefan Becker

“…mAbs…”
Get full text

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors by Geoff Hale, Alastair Douglas Davy, Ian Wilkinson

“…mAbs…”
Get full text